PU4760USw

In the Claims:

Please cancel claims 4-5 and 27. Please amend claims as follows 1, 22, 26 and 28.

1. (Currently Amended) A compound of formula (I):



I

wherein:

R^1 is selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay, Het, $-C(O)R^9$, -C(O)Ay, -C(O)Het, $-CO_2R^9$, $-C(O)NR^7R^8$, $-C(O)NR^7Ay$, $-C(S)NR^9R^{11}$, $-C(NH)NR^7R^8$, $-C(NH)NR^7Ay$, $-OR^7$, -OAy, -OHet, $-NR^7R^8$, $-NR^7Ay$, -NHHet, $-S(O)_nR^9$, $-S(O)_nAy$, $-S(O)_nHet$, $-S(O)_2NR^7R^8$, $-S(O)_2NR^7Ay$, $-R^{10}$cycloalkyl, $-R^{10}Ay$, $-R^{10}Het$, $-R^{10}OR^9$, $-R^{10}NR^7R^8$, $-R^{10}NR^7Ay$, $-R^{10}NHSO_2R^9$, $-R^{10}C(O)R^9$, $-R^{10}C(O)Ay$, $-R^{10}C(O)Het$, $-R^{10}CO_2R^9$, $-R^{10}OC(O)R^9$, $-R^{10}OC(O)Ay$, $-R^{10}OC(O)Het$, $-R^{10}C(O)NR^9R^{11}$, $-R^{10}C(O)NR^7Ay$, $-R^{10}C(O)NHR^{10}Het$, $-R^{10}C(S)NR^9R^{11}$, $-R^{10}C(NH)NR^9R^{11}$, $-R^{10}SO_2R^9$, $-R^{10}SO_2NR^9R^{11}$, $-R^{10}SO_2NHCOR^9$, $-R^{10}OS(O)_nR^9$, cyano, nitro and azido;

each R^7 and R^8 are the same or different and are independently selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, $-C(O)R^9$, $-CO_2R^9$, $-C(O)NR^9R^{11}$, $-C(S)NR^9R^{11}$, $-C(NH)NR^9R^{11}$, $-SO_2R^{10}$, $-SO_2NR^9R^{11}$, $-R^{10}$cycloalkyl, $-R^{10}Ay$, $-R^{10}Het$, $-R^{10}C(O)R^9$, $-R^{10}CO_2R^9$, $-R^{10}C(O)NR^9R^{11}$, $-R^{10}C(S)NR^9R^{11}$, $-R^{10}OR^9$, $-R^{10}NR^9R^{11}$, $-R^{10}NHCOR^9$, $-R^{10}NHC(NH)NR^9R^{11}$, $-R^{10}C(NH)NR^9R^{11}$, $-R^{10}NHSO_2R^9$, $-R^{10}SO_2NR^9R^{11}$, $-R^{10}SO_2R^{10}$ and $-R^{10}SO_2NHCOR^9$;

each R^9 and R^{11} are the same or different and are independently selected from the group consisting of H, alkyl, cycloalkyl, $-R^{10}$cycloalkyl, $-R^{10}OH$, $-R^{10}(OR^{10})_w$ where w is 1-10, and $-R^{10}NR^{10}R^{10}$;

each R^{10} is the same or different and is independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, and alkynyl;

n is 0, 1 or 2;

Ay is aryl;

Het is a 5- or 6-membered heterocyclic or heteroaryl group;

Y^1 is ~~N or~~ CH;

p is 0, 1 or 2 when Y^1 is CH,

~~p is 0 or 1 when Y^1 is N;~~

each R^6 is the same or different and is independently selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay, Het, $-C(O)R^9$, -C(O)Ay, -C(O)Het, $-CO_2R^9$, $-C(O)NR^7R^8$, $-C(O)NR^7Ay$, $-C(S)NR^9R^{11}$, $-C(NH)NR^7R^8$, $-C(NH)NR^7Ay$, $-OR^7$, -OAy, -OHet, $-NR^7R^8$, $-NR^7Ay$, -NHHet, $-S(O)_nR^9$, $-S(O)_nAy$, $-S(O)_nHet$, $-S(O)_2NR^7R^8$, $-S(O)_2NR^7Ay$, $-R^{10}$cycloalkyl, $-R^{10}Ay$, $-R^{10}Het$, $-R^{10}OR^9$, $-R^{10}NR^7R^8$, $-R^{10}NR^7Ay$, $-R^{10}NHSO_2R^9$, $-R^{10}C(O)R^9$, $-R^{10}C(O)Ay$, $-R^{10}C(O)Het$, $-R^{10}CO_2R^9$, $-R^{10}OC(O)R^9$, $-R^{10}OC(O)Ay$, $-R^{10}OC(O)Het$, $-R^{10}C(O)NR^9R^{11}$, $-R^{10}C(O)NR^7Ay$, $-R^{10}C(O)NHR^{10}Het$, $-R^{10}C(S)NR^9R^{11}$, $-R^{10}C(NH)NR^9R^{11}$, $-R^{10}SO_2R^9$, $-R^{10}SO_2NR^9R^{11}$, $-R^{10}SO_2NHCOR^9$, $-R^{10}OS(O)_nR^9$, cyano, nitro and azido;

or when p is 2, two adjacent R^6 groups together with the carbon atoms to which they are bonded form a cycloalkyl or a 5- or 6-membered heterocyclic group containing 1 or 2 heteroatoms;

Y is N or CH;

R^2 is selected from the group consisting of halo, alkyl, cycloalkyl, alkenyl, cycloalkenyl, Ay, Het, $-OR^7$, -OAy, -OHet $-NR^7R^8$, $-NR^7Ay$, -NHHet, $-S(O)_nR^9$, $-S(O)_nAy$, $-R^{10}NR^7R^8$ and $-R^{10}NR^7Ay$;

R^3 and R^4 are the same or different and are each independently selected from the group consisting of H, halo, alkyl, alkenyl, cycloalkyl, Ay, Het, $-C(O)R^7$, C(O)Ay, $-CO_2R^7$, $-CO_2Ay$, $-OR^7$, -OAy, $-NR^7R^8$, $-NR^7Ay$, -NHHet, $-SO_2NHR^9$, $-R^{10}OR^7$, $-R^{10}$cycloalkyl, $-R^{10}OAy$, $-R^{10}NR^7R^8$ and $-R^{10}NR^7Ay$;

Ring A is selected from the group consisting of aryl, 5-10 membered heterocyclic group and a 5-10 membered heteroaryl group;

q is 0, 1, 2, 3, 4 or 5; and

each R^5 is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay, Het, $-C(O)R^9$, -C(O)Ay, -C(O)Het, $-CO_2R^9$, $-C(O)NR^7R^8$, $-C(O)NR^7Ay$, $-C(S)NR^9R^{11}$, $-C(NH)NR^7R^8$, $-C(NH)NR^7Ay$, $-OR^7$, -OAy, -OHet, $-NR^7R^8$, $-NR^7Ay$, -NHHet, $-S(O)_nR^9$, $-S(O)_2NR^7R^8$, $-S(O)_2NR^7Ay$, $-R^{10}$cycloalkyl, $-R^{10}Het$, $-R^{10}C(O)R^9$, $-R^{10}CO_2R^9$, $-R^{10}C(O)NR^9R^{11}$, $-R^{10}C(O)NR^7Ay$, $-R^{10}C(O)NHR^{10}Het$, $-R^{10}C(S)NR^9R^{11}$, $-R^{10}C(NH)NR^9R^{11}$, $-R^{10}OR^9$, $-R^{10}NR^7R^8$, $-R^{10}NR^7Ay$, $-R^{10}SO_2R^9$, $-R^{10}SO_2NR^9R^{11}$, $-R^{10}SO_2NHCOR^9$, cyano, nitro and

azido; or

a pharmaceutically acceptable salt~~, solvate or physiologically functional derivative~~ thereof.

2. (Original) The compound according to claim 1 wherein R^1 is selected from the group consisting of halo, alkyl, cycloalkyl, Ay, Het, $-OR^7$, -OAy, $-NR^7R^8$, $-NR^7Ay$, -NHHet, $-S(O)_nR^9$, $-R^{10}$cycloalkyl, $-R^{10}OR^9$, $-R^{10}NR^7R^8$ and $-R^{10}NR^7Ay$.

3. (Original) The compound according to claim 1 wherein R^1 is selected from the group consisting of alkyl, Het, $-OR^7$, $-NR^7R^8$, $-NR^7Ay$ and $-S(O)_nR^9$.

4-5. (Canceled).

6. (Previously Presented) The compound according to claim 1 wherein p is 0 or 1.

7. (Previously Presented) The compound according to claim 1 wherein each R^6 is the same or different and is independently selected from the group consisting of halo, alkyl, Ay, Het, -C(O)Het, $-CO_2R^9$, $-C(O)NR^7R^8$, $-C(O)NR^7Ay$, $-OR^7$, -OAy, $-NR^7R^8$, $-NR^7Ay$, -NHHet, $-S(O)_nR^9$, $-S(O)_nAy$, $-S(O)_nHet$, $-R^{10}OR^9$ and cyano.

8. (Previously Presented) The compound according to claim 1 wherein each R^6 is the same or different and is independently selected from the group consisting of halo, alkyl, Het, $-NR^7R^8$, -NHHet and $-S(O)_nR^9$.

9. (Previously Presented) The compound according claim 1 wherein Y is CH.

10. (Previously Presented) The compound according to claim 1 wherein Y is N.

11. (Previously Presented) The compound according to claim 1 wherein R^2 is selected from the group consisting of Ay, Het, $-OR^7$, -OAy, -OHet, $-NR^7R^8$, $-NR^7Ay$, -NHHet, $-S(O)_nR^9$, $-S(O)_nAy$, $-R^{10}NR^7R^8$ and $-R^{10}NR^7Ay$.

12. (Previously Presented) The compound according to claim 1 wherein R^2 is selected from the group consisting of $-NR^7R^8$, $-NR^7Ay$ and -NHHet.

13. (Previously Presented) The compound according to claim 1 wherein R^3 and R^4 are the same or different and are each independently selected from the group consisting of H, halo, alkyl, Ay, $-CO_2R^7$, $-OR^7$, $-NR^7R^8$, $-R^{10}OR^7$ and $-R^{10}NR^7R^8$.

14. (Previously Presented) The compound according to claim 1 wherein R^3 and R^4 are both H.

15. (Previously Presented) The compound according to claim 1 wherein Ring A is selected from the group consisting of aryl, a 5-6 membered heterocyclic or heteroaryl group and a 9-membered heterocyclic or heteroaryl group.

16. (Previously Presented) The compound according to claim 1 wherein Ring A is selected from the group consisting of phenyl, naphthyl, furan, pyridine, pyrimidine, thiazol, pyrazine, pyrrole, imidazole, oxazole, benzimidazole, quinoline, isoquinoline and quinoxoline.

17. (Previously Presented) The compound according to claim 1 wherein Ring A is selected from the group consisting of phenyl, furan, pyridine and pyrimidine.

18. (Previously Presented) The compound according to claim 1 wherein Ring A is phenyl.

19. (Previously Presented) The compound according to claim 1 wherein q is 0, 1 or 2.

20. (Previously Presented) The compound according to claim 1 wherein each R^5 is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, Ay, Het, $-CO_2R^9$, $-C(O)NR^7R^6$, $-C(O)NR^7Ay$, $-OR^7$, -OAy, $-NR^7R^8$, $-NR^7Ay$, $-S(O)_2NR^7R^8$, cyano, nitro and azido.

21. (Previously Presented) The compound according to claim 1, wherein each R^5 is the same or different and is independently selected from the group consisting of halo, alkyl, $-OR^7$, $-NR^7R^8$ and cyano.

22. (Currently Amended) A compound selected from the group consisting of:

N-Cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-fluorophenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;

N-Cyclopentyl-3-[2-(cyclopropylamino)pyrimidin-4-yl]-2-(4-fluorophenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;

4-[2-(3-Chlorophenyl)pyrazolo[1,5-*c*]pyrimidin-3-yl]-*N*-cyclopentylpyrimidin-2-amine;

4-[2-(3-Chlorophenyl)-7-(methylthio)pyrazolo[1,5-*c*]pyrimidin-3-yl]-*N*-cyclopentylpyrimidin-2-amine;

2-(3-Chlorophenyl)-*N*-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-*c*]pyrimidin-7-amine;

4-[2-(3-Chlorophenyl)-7-(4-morpholinyl)pyrazolo[1,5-c]pyrimidin-3-yl]-N-cyclopentyl-2-pyrimidinamine;

2-(3-Chlorophenyl)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-*N*-(2-methoxyethyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;

2-(3-Chlorophenyl)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-*c*]pyrimidin-7-ol;

~~*N*-Cyclopentyl-8-(2-fluoro-4-pyridinyl)-2-(methylsulfanyl)-7-phenylpyrazolo[1,5-*a*][1,3,5]triazin-4-amine;~~

~~*N*2,*N*4-Dicyclopentyl-8-[2-(cyclopentylamino)-4-pyridinyl]-7-phenylpyrazolo[1,5-*a*][1,3,5]triazine-2,4-diamine;~~

~~*N*-cyclopentyl-8-[2-(cyclopentylamino)-4-pyrimidinyl]-7-phenylpyrazolo[1,5-*a*][1,3,5]triazin-4-amine;~~

3-[2-(Butylamino)pyrimidin-4-yl]-*N*-cyclopentyl-2-(4-fluorophenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;

3-(2-Anilinopyrimidin-4-yl)-*N*-cyclopentyl-2-(4-fluorophenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;

3-[2-(1,3-Benzothiazol-2-ylamino)pyrimidin-4-yl]-*N*-cyclopentyl-2-(4-fluorophenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;

N-Cyclopentyl-2-(4-fluorophenyl)-3-{2-[(4-methyl-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}pyrazolo[1,5-c]pyrimidin-7-amine;

3-[2-(1*H*-Benzimidazol-2-ylamino)pyrimidin-4-yl]-*N*-cyclopentyl-2-(4-fluorophenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;

N-Cyclopentyl-3-{2-[(4-fluorobenzyl)amino]pyrimidin-4-yl}-2-(4-fluorophenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;

N-Cyclopentyl-2-(4-fluorophenyl)-3-{2-[(2-phenylethyl)amino]pyrimidin-4-yl}pyrazolo[1,5-*c*]pyrimidin-7-amine;

3-[2-(*tert*-Butylamino)pyrimidin-4-yl]-*N*-cyclopentyl-2-(4-fluorophenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;

N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-(methylsulfanyl)pyrazolo[1,5-*c*]pyrimidin-3-yl]pyrimidin-2-amine;

N-Cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;

4-{7-(Cyclopentylamino)-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-*c*]pyrimidin-2-yl}phenol;

3-[2-(Cyclopentylamino)pyrimidin-4-yl]-*N*-cyclopropyl-2-(4-methoxyphenyl)pyrazolo-[1,5-*c*]pyrimidin-7-amine;

2-(4-Butoxyphenyl)-*N*-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-*c*]pyrimidin-7-amine;

N-Cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-isobutoxyphenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;

N-Cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-[4-(2-methoxyethoxy)phenyl]pyrazolo[1,5-*c*]pyrimidin-7-amine;

N-Cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-propoxyphenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;

N-(*tert*-Butyl)-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-fluorophenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;

N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-pyrrolidin-1-ylpyrazolo[1,5-*c*]pyrimidin-3-yl]pyrimidin-2-amine; and

N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-piperidin-1-ylpyrazolo[1,5-*c*]pyrimidin-3-yl]pyrimidin-2-amine, or

a pharmaceutically acceptable salt~~, solvate or physiologically functional derivative~~ thereof.

23. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1.

24. (Original) The pharmaceutical composition according to claim 23 further comprising a pharmaceutically acceptable carrier or diluent.

25. (Previously Presented) The pharmaceutical composition according to claim 23 further comprising an antiviral agent selected from the group consisting of aciclovir and valaciclovir.

26. (Currently Amended) A method for the ~~prophylaxis or~~ treatment of a herpes viral infection selected from herpes simplex virus 1 and herpes simplex virus 2, in an animal, said method comprising administering to the animal a therapeutically effective amount of a compound according to claim 1.

27. (Canceled)

28. (Currently Amended) A method for the ~~prophylaxis or~~ treatment of a condition or disease associated with a herpes viral infection selected from herpes simplex virus 1 and herpes simplex virus 2, in an animal, comprising administering to the animal a therapeutically effective amount of the compound of formula (I) according to claim 1.

29. (Previously Presented) A process for preparing a compound according to any claim 1 wherein Y^1 is CH; Y is N; R^2 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, Ay, Het, $-OR^7$, -OAy, -OHet $-NR^7R^8$, $-NR^7Ay$, -NHHet $-S(O)_nR^8$, $-S(O)_nAy$, $-R^{10}NR^7R^8$ and $-R^{10}NR^7Ay$; and R^3 and R^4 are H, said process comprising reacting a compound of formula (XX):



XX

with a compound of formula (XXI):



XXI

30. (Previously Presented) A process for preparing a compound according to claim 1 wherein Y is N; R^2 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, Ay, Het, $-OR^7$, -OAy, -OHet $-NR^7R^8$, $-NR^7Ay$, -NHHet $-S(O)_nR^9$, $-S(O)_nAy$, $-R^{10}NR^7R^8$ and $-R^{10}NR^7Ay$; R^3 is selected from the group consisting of H, alkyl, alkenyl, cycloalkyl, Ay, Het, $-C(O)R^7$, C(O)Ay, $-CO_2R^7$, $-CO_2Ay$, $-OR^7$, -OAy, $-NR^7R^8$ (where R^7 and R^8 are not H), $-NR^7Ay$ (where R^7 is H), $-SO_2NHR^8$, $-R^{10}OR^7$, $-R^{10}$cycloalkyl, $-R^{10}OAy$, $-R^{10}NR^7R^8$ and $-R^{10}NR^7Ay$; and R^4 is H said process comprising reacting a compound of formula (XXV):



XXV

with a compound of formula (XXI):



XXI

31. (Previously Presented) A process for preparing a compound according to claim 1 wherein Y is N and R^2 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, Ay, Het, $-OR^7$, -OAy, -OHet $-NR^7R^8$, $-NR^7Ay$, -NHHet $-S(O)_nR^9$, $-S(O)_nAy$, $-R^{10}NR^7R^8$ and $-R^{10}NR^7Ay$, said process comprising the steps of:

a) reacting a compound of formula (XXVIII):



XXVIII

with a compound of formula (XXI):



XXI

to prepare an intermediate compound; and

b) oxidizing the intermediate compound.

32. (Previously Presented) A process for preparing a compound according to claim 1 comprising reacting a compound of formula (XXX):



XXX

wherein X^1 is chloro, bromo or iodo;

with a compound of formula (X):



X

wherein M^1 is $-B(OH)_2$, $-B(ORa)_2$, $-B(Ra)_2$, $-Sn(Ra)_3$, Zn-halide, ZnRa, or Mg-halide where Ra is alkyl or cycloalkyl and halide is halo.

33-40. (Canceled)